In a groundbreaking multicenter clinical trial, scientists have determined that integrating an innovative adenoviral-based viral immunotherapy, known as aglatimagene besadenovec (CAN-2409), alongside conventional radiation therapy significantly enhances disease-free survival rates in patients diagnosed with intermediate- to high-risk localized prostate cancer. This landmark study, spearheaded by a team of researchers at Johns Hopkins University School of Medicine and its affiliated cancer and urological institutes, heralds a potential paradigm shift in the management of prostate cancer, which remains a leading cause of cancer-related morbidity in men worldwide.
This pivotal phase 3 trial evaluated 745 men presenting with prostate cancer confined strictly to the prostate gland, yet characterized by clinical features suggesting a considerable risk for tumor recurrence or metastasis. The participants were enrolled across 51 diverse clinical sites spanning the United States and Puerto Rico, ensuring a comprehensive demographic and clinical diversity. The experimental design involved administering targeted injections of aglatimagene directly into the prostate tissue, combined with the oral administration of valacyclovir, a prodrug whose activation is localized to the prostate microenvironment, concurrently with standard radiation protocols. A control cohort received placebo injections alongside valacyclovir and radiation, establishing a robust comparative framework for evaluating therapeutic efficacy.
Mechanistically, aglatimagene besadenovec employs a genetically engineered adenovirus vector designed to deliver a suicide gene selectively into malignant prostate cells. Once transduced, and upon administration of valacyclovir, the prodrug is metabolically converted into a cytotoxic agent specifically within the infected tumor milieu. This targeted activation disrupts DNA replication selectively within cancerous cells, instigating apoptosis. Additionally, this viral-immunotherapeutic approach promotes a potent, localized immune response, recruiting and activating immune effector cells to target residual tumor foci, a dual modality that underpins its therapeutic promise.
At a median follow-up interval exceeding four years, the trial demonstrated that patients receiving the aglatimagene regimen exhibited a statistically significant extension of disease-free survival compared to the placebo group. Notably, cancer progression, recurrence, or mortality was observed in only 23% of the treated cohort, juxtaposed against 31% in the control arm. Intriguingly, median disease-free survival had not been reached in the investigational group at the time of analysis, underscoring a durable therapeutic effect, whereas the median survival in the placebo group was estimated at approximately 86 months.
Further reinforcing clinical impact, patients treated with aglatimagene displayed superior biochemical control, evidenced by a markedly higher proportion achieving very low prostate-specific antigen (PSA) levels—a biomarker strongly correlated with disease control and prognosis. Substantiating radiologic and pathological findings, post-radiation biopsies assessed at two years revealed a remarkable 80% negative biopsy rate in the aglatimagene cohort, as opposed to 63% in the placebo group, highlighting effective tumor eradication.
Importantly, this augmented therapeutic activity did not correspond with a significant increase in adverse events. The severity profile of side effects remained predominantly mild to moderate with comparable incidence of serious treatment-related toxicity between study arms (8% in the aglatimagene group versus 7% in placebo). Crucially, no treatment-associated mortality was documented, underscoring the favorable safety margin of this viral immunotherapy when combined with radiation.
These findings underscore the mechanism-based rationale behind utilizing a viral vector to introduce suicide genes selectively targeting tumor cells while stimulating anti-tumor immunity, addressing the unmet clinical need for more effective and less toxic prostate cancer therapies. Given that approximately 30% of patients with localized intermediate- to high-risk disease traditionally experience relapse post-curative interventions, aglatimagene besadenovec represents a much-needed advancement capable of altering disease trajectories and improving long-term outcomes.
The study, financially supported in part by the National Institutes of Health and conducted under an FDA Special Protocol Assessment, emphasizes the importance of extensive, regulated clinical evaluation for novel immunotherapies. The promising results reported validate earlier phase data and provide a strong regulatory and clinical foundation for potential approval, paving the way for integration into standard prostate cancer treatment algorithms.
Leading prostate cancer experts, including Theodore DeWeese, M.D., the principal investigator, emphasize that aglatimagene besadenovec could become the first new frontline therapeutic addition for localized prostate cancer in over two decades, reflecting a major step forward in disease management. The viral immunotherapy’s dual action — direct oncolysis via gene-mediated cytotoxicity combined with immunomodulatory effects — represents a sophisticated approach aligned with the evolving landscape of precision oncology.
Long-term follow-up remains critical to fully elucidate whether this treatment combination not only prolongs disease-free intervals but also mitigates the necessity for subsequent salvage therapies, such as androgen deprivation therapy, and ultimately impacts overall survival. Current data provide compelling evidence for incorporating immunovirotherapy into multidisciplinary prostate cancer care, expanding beyond conventional modalities alone.
The research team also highlighted the collaborative efforts of numerous urology and oncology centers, reflecting a concerted national effort to tackle the challenges of prostate cancer recurrence and improve patient quality of life. By selectively harnessing viral vectors to intelligently target tumor biology and harness host immunity, aglatimagene besadenovec represents a beacon of hope for men confronting this disease.
In summary, this multicenter clinical trial convincingly demonstrates that the addition of an adenoviral-based viral immunotherapy to established radiation treatments substantially enhances disease-free survival in men harboring intermediate- and high-risk localized prostate cancer. The investigational agent’s promising efficacy and manageable safety profile could signal a transformative advance in prostate cancer therapeutics, underpinning ongoing investigations aimed at solidifying its role in clinical practice.
Subject of Research: Adenoviral-based viral immunotherapy (aglatimagene besadenovec) in localized prostate cancer
Article Title: Not provided
News Publication Date: June 1, 2023
Web References:
- Johns Hopkins University School of Medicine: https://www.hopkinsmedicine.org/som
- Johns Hopkins Kimmel Cancer Center: https://www.hopkinsmedicine.org/kimmel-cancer-center
- Department of Radiation Oncology and Molecular Radiation Sciences: https://www.hopkinsmedicine.org/radiation-oncology
- Brady Urological Institute: https://www.hopkinsmedicine.org/brady-urology-institute
- The Lancet Oncology: https://www.thelancet.com/journals/lanonc/home
References: The multicenter clinical trial publication in The Lancet Oncology, June 1, 2023
Image Credits: Courtesy of the Johns Hopkins University School of Medicine
Keywords: Prostate cancer, viral immunotherapy, aglatimagene besadenovec, adenoviral vector, radiation therapy, disease-free survival, valacyclovir, phase 3 clinical trial, prostate-specific antigen, immune response, targeted gene therapy, cancer recurrence
